Advanced malignant solid tumors Clinical Trials

16 recruitingLast updated: June 18, 2026

There are 16 actively recruiting advanced malignant solid tumors clinical trials across 4 countries. Studies span Phase 1, Not Applicable, Phase 2. Top locations include Shanghai, Shanghai Municipality, China, Beijing, Beijing Municipality, China, San Antonio, Texas, United States. Updated daily from ClinicalTrials.gov.


Advanced malignant solid tumors Trials at a Glance

16 actively recruiting trials for advanced malignant solid tumors are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 12 trials, with the heaviest enrollment activity in Shanghai, Beijing, and San Antonio. Lead sponsors running advanced malignant solid tumors studies include Shanghai Junshi Bioscience Co., Ltd., Zhejiang University, and FindCure Biosciences (ZhongShan) Co., Ltd..

Browse advanced malignant solid tumors trials by phase

Treatments under study

About Advanced malignant solid tumors Clinical Trials

Looking for clinical trials for Advanced malignant solid tumors? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced malignant solid tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced malignant solid tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 2

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Shanghai Junshi Bioscience Co., Ltd.410 enrolled1 locationNCT07480733
Recruiting
Phase 1

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Advanced malignant solid tumorsMetastatic Malignant Solid Tumors
Genmab45 enrolled5 locationsNCT06573294
Recruiting
Not Applicable

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.30 enrolled1 locationNCT06658951
Recruiting
Phase 1Phase 2

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
FindCure Biosciences (ZhongShan) Co., Ltd.33 enrolled1 locationNCT06499350
Recruiting
Phase 1

A Study of CSCJC3456 in Patients With Advanced Malignant Tumors

Advanced malignant solid tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.102 enrolled2 locationsNCT06717750
Recruiting
Phase 1

JSKN022 in Subjects With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd225 enrolled1 locationNCT07292402
Recruiting
Not Applicable

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors
Zhejiang University24 enrolled1 locationNCT07010523
Recruiting
Phase 1

MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors

B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
Zhejiang University12 enrolled1 locationNCT06912152
Recruiting
Not Applicable

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Advanced malignant solid tumors
The First Affiliated Hospital of Nanchang University20 enrolled1 locationNCT05749627
Recruiting
Phase 1

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

Advanced malignant solid tumors
Shanghai Junshi Bioscience Co., Ltd.93 enrolled1 locationNCT06571422
Recruiting
Phase 1Phase 2

A Study of GQ1010 in Subjects With Advanced Solid Tumors

Advanced malignant solid tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.260 enrolled5 locationsNCT06464055
Recruiting
Phase 1

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Peking University Cancer Hospital & Institute13 enrolled1 locationNCT06728189
Recruiting
Phase 1

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Mabwell (Shanghai) Bioscience Co., Ltd.40 enrolled2 locationsNCT05773937
Recruiting
Phase 1

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

CDH17-positive Advanced Malignant Solid Tumors
Shanghai Pudong Hospital17 enrolled1 locationNCT06501183
Recruiting
Phase 1

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Advanced malignant solid tumors
Hutchmed81 enrolled1 locationNCT05886374